Placebo matching DBPR108; Sitagliptin; DBPR108 — Competitive Intelligence Brief

Placebo matching DBPR108; Sitagliptin; DBPR108 (Placebo matching DBPR108; Sitagliptin; DBPR108) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4) Diabetes Small molecule

Target snapshot

Placebo matching DBPR108; Sitagliptin; DBPR108 (Placebo matching DBPR108; Sitagliptin; DBPR108) — CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and stimulate insulin secretion in response to glucose.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo matching DBPR108; Sitagliptin; DBPR108 TARGET	Placebo matching DBPR108; Sitagliptin; DBPR108	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	phase 3	DPP-4 inhibitor	DPP-4 (Dipeptidyl peptidase-4)
SGLT2 inhibitor and DPP-4 inhibitor	SGLT2 inhibitor and DPP-4 inhibitor	LMC Diabetes & Endocrinology Ltd.	marketed	SGLT2 inhibitor and DPP-4 inhibitor combination	SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)
SGLT2i+Metformin+Linagliptin	SGLT2i+Metformin+Linagliptin	Huazhong University of Science and Technology	marketed	Combination antidiabetic agent (SGLT2 inhibitor + biguanide + DPP-4 inhibitor)	SGLT2 transporter, mitochondrial complex I (metformin), dipeptidyl peptidase-4
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Sitagliptin (Januvia)	Sitagliptin (Januvia)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Metformin / alogliptin Oral Product	Metformin / alogliptin Oral Product	University of Catanzaro	marketed	Biguanide / DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Alogliptin: dipeptidyl peptidase-4 (DPP-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class